In the current study, we wondered whether the levels of NGAL in the CSF were different in patients with BM, TBM, or CM and whether the CSF NGAL could be used as a biomarker for distinguishing BM from TBM or CM. This evidence concerns the gene LCN2 and meningeal tuberculosis.